Biotech Values

[WorstLuck]

1) Co is unlikely to advance drug themselves ( so probably no capital raise after this :--). Mgt says to big a market to take on by themselves .

Good for them. It looks like they were looking for a much larger dose response closer to Eyelea or a tki and didn't get it. Knowing when to cut a project is a good sign.

https://x.com/BiotechElmo/status/1793035993991266771/photo/1

That's pretty random and very weak. I can't say no one will ever explore further or repurpose but it looks unlikely to draw any interest IMHO.

If there is a real drug there it would be fantastic in that it could maintain CST with very low levels of variation - that is the potential value since there would be less fibrosis. eos.